REVIEW article

Front. Immunol.

Sec. Vaccines and Molecular Therapeutics

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1578733

Progress on the Combination Vaccines and Co-administration of Influenza Virus and SARS-CoV-2 Vaccines

Provisionally accepted
Chengyu HuChengyu Hu1Chenguang NiuChenguang Niu1Ke HeKe He2Mengyu LiMengyu Li2Xiaonan GaoXiaonan Gao2Qiannan WeiQiannan Wei1Weiyang SunWeiyang Sun3Yongkun ZhaoYongkun Zhao3Yuanguo LiYuanguo Li3Yuwei GaoYuwei Gao3Zhiguang RenZhiguang Ren1,3,4*Wang TiechengWang Tiecheng3*Xianzhu XiaXianzhu Xia3*
  • 1First Affiliated Hospital of Henan University, Kaifeng, Henan Province, China
  • 2School of Pharmacy, Henan University, Kaifeng, Henan Province, China
  • 3Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, Hebei Province, China
  • 4School of Basic Medical Sciences, Henan University, Kaifeng, Henan Province, China

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

The COVID-19 and seasonal influenza have taken a huge toll on the global economy and health condition. Given the potential of COVID-19 to transform into a chronic epidemic akin to seasonal influenza, Influenza virus and SARS-CoV-2 will continue to be a significant threat to healthcare for some time to come. Coinfection involving the two viruses has been proven to worsen the severity of the illness, as evidenced by clinical observational data. And vaccination remains the most effective measure in the prevention and treatment of infectious diseases. In addition, the coadministration of influenza virus and SARS-CoV-2 vaccines offered greater benefits than either vaccine alone. Combination vaccines are also a major hotspot in novel vaccine development. This review highlights the advancements in the development of combined vaccines for COVID-19 and seasonal influenza, as demonstrated in animal studies and clinical trials, and emphasizes the importance of combined vaccine.

Keywords: SARS-CoV-2, Influenza Virus, Coinfection, Coadministration, Combined vaccines

Received: 18 Feb 2025; Accepted: 25 Apr 2025.

Copyright: © 2025 Hu, Niu, He, Li, Gao, Wei, Sun, Zhao, Li, Gao, Ren, Tiecheng and Xia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Zhiguang Ren, First Affiliated Hospital of Henan University, Kaifeng, Henan Province, China
Wang Tiecheng, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, 130122, Hebei Province, China
Xianzhu Xia, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, 130122, Hebei Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material